Article

The lived experience of breast cancer patients on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiation

2023-01-30

Abstract excerpt

<title>Abstract</title> <p><bold>Purpose</bold> Breast cancer in women is the most commonly diagnosed cancer. Adjuvant endocrine therapy (AET) showed consistent improvements in recurrence and survival rates. Adherence to adjuvant endocrine therapy remains essential for improving overall survival in women with hormone receptor (HR) positive breast cancer. However, early discontinuation of medicine is reported to r...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 15f2ab0a-248e-557b-92b1-a3e1f3508942
DOI: 10.21203/rs.3.rs-2497342/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The lived experience of breast cancer patients on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiationDOI 10.21203/rs.3.rs-2497342/v1Read

Patients’ experience of medication brand changes during hormone therapy for breast cancer. An Interpretative Phenomenological AnalysisSemantic proximity Read

Assessment of compliance with hormonal therapy in early breast cancer patients with positive hormone receptor phenotype: A single institution study.Semantic proximity Read

Clinical and biomarker predictors of side effects from tamoxifen.Semantic proximity Read

Preventing metastatic recurrence in low-risk ER/PR+ breast cancer patients – a retrospective clinical study exploring the evolving challenge of persistence with adjuvant endocrine therapySemantic proximity Read

Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors.Semantic proximity Read

The Value of Oral Selective Estrogen Receptor Degraders in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer after Progression on ≥ 1 Line of Endocrine Therapy: Systematic Review and Meta-analysisSemantic proximity Read

Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study.Semantic proximity Read

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy.Semantic proximity Read

Tolerance to oral anticancer agent treatment in older adults with cancer: A secondary analysis of data from EHRs and a pilot study of patient-reported outcomesSemantic proximity Read

Exogenous reproductive hormone use in breast cancer survivors and previvors.Semantic proximity Read

Racial and ethnic differences in adjuvant hormonal therapy use.Semantic proximity Read

Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy.Semantic proximity Read